open access

Vol 15, No 2 (2020)
Heart failure
Published online: 2020-08-31
Get Citation

The summary of the 2019 year in heart failure with reduced ejection fraction

Małgorzata Lelonek
DOI: 10.5603/FC.2020.0025
·
Folia Cardiologica 2020;15(2):176-181.

open access

Vol 15, No 2 (2020)
Heart failure
Published online: 2020-08-31

Abstract

The last years it is a good time in heart failure for innovative therapy. The results of new trials which were published after the last 2016 guidelines for heart failure need the systematic approach and present the practical guide based on EBM. For that reason in the last year 2019 the experts of Heart Failure Association (HFA) European Society of Cardiology published the consensus. The present article summarized the main issues regarding heart failure with reduced ejcetion fraction together with comennt based on the HFA expert consensus.

Abstract

The last years it is a good time in heart failure for innovative therapy. The results of new trials which were published after the last 2016 guidelines for heart failure need the systematic approach and present the practical guide based on EBM. For that reason in the last year 2019 the experts of Heart Failure Association (HFA) European Society of Cardiology published the consensus. The present article summarized the main issues regarding heart failure with reduced ejcetion fraction together with comennt based on the HFA expert consensus.

Get Citation

Keywords

heart failure; reduced ejection fraction of left ventrice, therapy

About this article
Title

The summary of the 2019 year in heart failure with reduced ejection fraction

Journal

Folia Cardiologica

Issue

Vol 15, No 2 (2020)

Pages

176-181

Published online

2020-08-31

DOI

10.5603/FC.2020.0025

Bibliographic record

Folia Cardiologica 2020;15(2):176-181.

Keywords

heart failure
reduced ejection fraction of left ventrice
therapy

Authors

Małgorzata Lelonek

References (18)
  1. Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21(10): 1169–1186.
  2. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  3. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018; 138(17): 1904–1907.
  4. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019; 139(11): 1384–1395.
  5. Claggett B, Lachin JM, Hantel S, et al. Long-term benefit of empagliflozin on life expectancy in patients with type 2 diabetes mellitus and established cardiovascular disease. Circulation. 2018; 138(15): 1599–1601.
  6. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
  7. Vaduganathan M, Claggett BL, Solomon SD. How do SGLT-2 inhibitors work to prevent heart failure? JACC Heart Fail. 2020; 8(1): 67–69.
  8. Claggett B, Packer M, McMurray JJV, et al. PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015; 373(23): 2289–2290.
  9. Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5): 333–340.
  10. Desai AS, Vardeny O, Claggett B, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid Receptor Antagonists by Use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017; 2(1): 79–85.
  11. Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018; 6(6): 489–498.
  12. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21(8): 998–1007.
  13. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  14. Komajda M, Anker SD, Cowie MR, et al. QUALIFY Investigators. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016; 18(5): 514–522.
  15. Komajda M, Cowie MR, Tavazzi L, et al. QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017; 19(11): 1414–1423.
  16. Ouwerkerk W, Voors AA, Anker SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J. 2017; 38(24): 1883–1890.
  17. Opolski G, Ozierański K, Lelonek M, et al. Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med. 2017; 127(10): 657–665.
  18. Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018; 20(9): 1315–1322.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl